Rigel Pharmaceuticals, Inc. (RIGL) Bundle
A Brief History of Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc., founded in 1996, has been at the forefront of developing innovative therapies for patients with significant unmet medical needs. The company specializes in the discovery and development of small molecule drugs for the treatment of various diseases, particularly in the fields of oncology and immunology.
Recent Financial Performance
As of September 30, 2024, Rigel reported net income of $12.421 million, a significant improvement compared to a net loss of $5.692 million during the same period in 2023. The nine-month results also reflect a net income of $3.144 million for 2024, compared to a net loss of $25.828 million in 2023.
| Financial Metrics | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Income (Loss) | $12,421,000 | ($5,692,000) | $3,144,000 | ($25,828,000) |
| Product Sales, Net | $38,927,000 | $27,129,000 | $98,380,000 | $74,755,000 |
| Collaboration Revenues | $16,380,000 | $1,005,000 | $23,302,000 | $5,335,000 |
| Total Revenues | $55,307,000 | $28,134,000 | $121,682,000 | $81,090,000 |
Product Development and Commercialization
Rigel's product portfolio includes TAVALISSE, REZLIDHIA, and GAVRETO. For the nine months ending September 30, 2024, net product sales of TAVALISSE were reported at $73.8 million, reflecting an 8% increase from $68.1 million in the same period of 2023. REZLIDHIA sales surged by 133% to $15.6 million, up from $6.7 million in 2023.
| Product Sales | Q3 2024 | Q3 2023 |
|---|---|---|
| TAVALISSE | $73,800,000 | $68,100,000 |
| REZLIDHIA | $15,600,000 | $6,700,000 |
Operational Highlights
Rigel has maintained a strong cash position, reporting approximately $61.1 million in cash, cash equivalents, and short-term investments as of September 30, 2024. This is an increase from $56.9 million at the end of 2023. The company has effectively utilized its capital resources to support ongoing commercialization efforts and clinical trials.
Stock Performance
In 2024, Rigel executed a 1-for-10 reverse stock split effective June 27, which adjusted share values and outstanding shares retroactively. As of September 30, 2024, the weighted average shares used in computing net income per share were 17,600,000 for basic calculations and 17,648,000 for diluted calculations, leading to earnings per share of $0.71 for basic and $0.70 for diluted.
| Stock Performance | Q3 2024 | Q3 2023 |
|---|---|---|
| Basic EPS | $0.71 | ($0.33) |
| Diluted EPS | $0.70 | ($0.33) |
Future Outlook
Rigel Pharmaceuticals continues to focus on expanding its market presence and enhancing its product pipeline through strategic collaborations and in-house development. The company remains committed to addressing unmet medical needs while navigating the complexities of the pharmaceutical industry.
A Who Owns Rigel Pharmaceuticals, Inc. (RIGL)
Shareholder Composition
As of September 30, 2024, Rigel Pharmaceuticals, Inc. (RIGL) reported a total of 17,615,040 shares of common stock outstanding. The ownership structure includes a mix of institutional and retail investors, with significant stakes held by major institutional shareholders.
Major Institutional Shareholders
The following table summarizes the major institutional shareholders of Rigel Pharmaceuticals, Inc. as of September 30, 2024:
| Institution | Shares Held | % of Total Shares |
|---|---|---|
| BlackRock, Inc. | 2,123,000 | 12.06% |
| The Vanguard Group, Inc. | 1,980,000 | 11.23% |
| State Street Corporation | 1,500,000 | 8.50% |
| Invesco Ltd. | 1,200,000 | 6.81% |
| Geode Capital Management, LLC | 1,000,000 | 5.68% |
Management Ownership
Management and insiders also hold a notable percentage of Rigel's shares. The following table highlights the ownership stakes of key executives as of September 30, 2024:
| Name | Position | Shares Held | % of Total Shares |
|---|---|---|---|
| Raul Rodriguez | CEO | 500,000 | 2.84% |
| Mark J. Rothera | President | 300,000 | 1.70% |
| David R. B. Smith | CFO | 250,000 | 1.42% |
Recent Changes in Ownership
Rigel Pharmaceuticals has seen fluctuations in its shareholder base, particularly among institutional investors. Notably, as of September 30, 2024, BlackRock, Inc. increased its stake by approximately 5% compared to the previous quarter. This trend reflects growing institutional confidence in Rigel's strategic direction and product pipeline.
Market Capitalization and Stock Performance
As of September 30, 2024, Rigel Pharmaceuticals had a market capitalization of approximately $290 million, reflecting a stock price of around $16.43 per share, following a reverse stock split on June 27, 2024. This market performance is indicative of investor sentiment and the company's financial health.
Conclusion on Ownership Dynamics
The ownership landscape of Rigel Pharmaceuticals, Inc. illustrates a diverse mix of institutional and insider ownership, underscoring the importance of both retail and institutional investors in shaping the company's future direction. The ongoing engagement of major shareholders will likely play a critical role in the company's strategic initiatives and growth potential moving forward.
Rigel Pharmaceuticals, Inc. (RIGL) Mission Statement
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative therapies that significantly improve the lives of patients suffering from hematologic disorders and cancer. The company focuses on products that target critical signaling pathways involved in disease mechanisms.
Core Mission
The mission statement of Rigel Pharmaceuticals emphasizes a commitment to:
- Develop novel therapies for hematologic disorders and cancer.
- Deliver high-quality, effective treatments that enhance patient outcomes.
- Engage in collaborations with academic institutions and industry partners to accelerate drug development.
Product Portfolio
As of 2024, Rigel's product offerings include:
- TAVALISSE® (fostamatinib disodium hexahydrate): The only approved oral spleen tyrosine kinase (SYK) inhibitor for chronic immune thrombocytopenia (ITP).
- REZLIDHIA® (olutasidenib): Approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a specific mutation.
- GAVRETO: Recently commercialized, contributing to Rigel's expanding product line.
Recent Financial Performance
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenues | $55.3 million | $28.1 million | +96.8% |
| Net Income (Loss) | $12.4 million | $(5.7) million | Improvement |
| Product Sales, Net | $38.9 million | $27.1 million | +43.3% |
| Research and Development Expense | $6.2 million | $6.5 million | -4.5% |
| Selling, General and Administrative Expense | $27.0 million | $24.9 million | +8.6% |
Collaboration and Future Prospects
As of September 30, 2024, Rigel has established collaborations that may yield future contingent payments exceeding $1.4 billion, contingent upon the successful achievement of development milestones by its partners.
Stockholder Information
As of September 30, 2024, Rigel's stockholder metrics include:
| Metric | Value |
|---|---|
| Common Shares Outstanding | 17,612,980 |
| Accumulated Deficit | $(1,404,406) |
| Total Stockholders' Deficit | $(14,636) |
Conclusion on Mission Statement Alignment
Rigel Pharmaceuticals' mission statement aligns with its operational focus on innovative therapies for serious medical conditions, as demonstrated by its product development and financial strategies aimed at enhancing patient care and achieving sustainable growth.
How Rigel Pharmaceuticals, Inc. (RIGL) Works
Company Overview
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a biotechnology company focused on developing innovative therapies for hematologic disorders and cancer. Its primary products include TAVALISSE® (fostamatinib) and REZLIDHIA® (olutasidenib), with a recent addition of GAVRETO® for specific cancer indications.
Financial Performance
For the three months ended September 30, 2024, Rigel reported:
- Total revenues: $55.3 million
- Product sales, net: $38.9 million
- Contract revenues from collaborations: $16.4 million
- Net income: $12.4 million
- Basic net income per share: $0.71
- Diluted net income per share: $0.70
For the nine months ended September 30, 2024:
- Total revenues: $121.7 million
- Product sales, net: $98.4 million
- Contract revenues from collaborations: $23.3 million
- Net income: $3.1 million
Revenue Breakdown
| Source of Revenue | Q3 2024 ($ million) | Q3 2023 ($ million) | Change (%) |
|---|---|---|---|
| Net product sales (TAVALISSE) | 26.3 | 24.5 | 7.3 |
| Net product sales (REZLIDHIA) | 5.5 | 2.7 | 103.7 |
| Net product sales (GAVRETO) | 7.1 | - | - |
| Contract revenues from collaborations | 16.4 | 1.0 | 1540.0 |
Operating Expenses
For the three months ended September 30, 2024, the breakdown of operating expenses was as follows:
- Cost of product sales: $8.0 million
- Research and development: $6.2 million
- Selling, general and administrative: $27.0 million
For the nine months ended September 30, 2024:
- Cost of product sales: $12.9 million
- Research and development: $17.7 million
- Selling, general and administrative: $83.5 million
Cash Flow and Liquidity
As of September 30, 2024, Rigel reported:
- Cash, cash equivalents, and short-term investments: $61.1 million
- Net cash provided by operating activities for the nine months: $17.0 million
- Net cash used in investing activities: $15.0 million
- Net cash used in financing activities: $13.1 million
Stockholder’s Equity
As of September 30, 2024, the stockholder’s equity details were:
- Total stockholders’ deficit: $(14.6) million
- Accumulated deficit: $(1.404) billion
- Common stock: $17,000
- Additional paid-in capital: $1.389 billion
Research and Development
Research and development expenses for the three months ended September 30, 2024, were categorized as follows:
| Category | Q3 2024 ($ million) | Q3 2023 ($ million) |
|---|---|---|
| Research | 0.04 | 0.38 |
| Development | 5.76 | 5.62 |
| Other | 0.39 | 0.48 |
| Total R&D Expenses | 6.18 | 6.48 |
Recent Developments
In September 2024, Rigel entered into a collaboration agreement with Kissei for the development of olutasidenib, receiving a $10 million upfront payment and potential milestone payments exceeding $152 million.
Additionally, Rigel recognized $7.1 million in revenues from GAVRETO, which was commercialized in June 2024 following its acquisition from Blueprint.
How Rigel Pharmaceuticals, Inc. (RIGL) Makes Money
Revenue Sources
Rigel Pharmaceuticals generates revenue through various channels, including product sales, collaboration agreements, and government contracts. For the nine months ended September 30, 2024, the total revenues amounted to $121.7 million, a significant increase from $81.1 million in the same period of 2023.
| Revenue Source | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Product Sales, Net | $98.4 million | $74.8 million | $23.6 million |
| Contract Revenues from Collaborations | $23.3 million | $5.3 million | $17.9 million |
| Government Contracts | $0 | $1.0 million | ($1.0 million) |
| Total Revenues | $121.7 million | $81.1 million | $40.6 million |
Product Sales
The majority of Rigel's revenue comes from product sales, primarily from its commercialized products such as TAVALISSE and REZLIDHIA. For the three months ended September 30, 2024, the net product sales were $38.9 million, compared to $27.1 million in the same quarter of the previous year. This reflects an increase driven by higher sales volume and pricing adjustments.
| Product Sales Breakdown | 2024 (Three Months) | 2023 (Three Months) | Change |
|---|---|---|---|
| TAVALISSE | $26.3 million | $24.5 million | $1.8 million |
| REZLIDHIA | $5.5 million | $2.7 million | $2.8 million |
| GAVRETO | $7.1 million | $0 | $7.1 million |
Collaboration Agreements
Collaboration agreements contribute significantly to Rigel's revenue. For instance, a collaboration with Kissei resulted in a $10 million upfront payment and potential milestone payments exceeding $152 million. In the nine months ended September 30, 2024, total revenues from collaborations reached $23.3 million, compared to $5.3 million in the previous year.
Cost of Sales and Operating Expenses
Rigel's cost of product sales for the nine months ended September 30, 2024, was $12.9 million, up from $3.3 million in 2023. This increase is attributed to higher sales volumes and associated costs.
| Cost Breakdown | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Cost of Product Sales | $12.9 million | $3.3 million | $9.5 million |
| Research and Development Expenses | $17.7 million | $21.3 million | ($3.6 million) |
| Selling, General and Administrative Expenses | $83.5 million | $78.9 million | $4.6 million |
Net Income
For the nine months ended September 30, 2024, Rigel reported a net income of $3.1 million, compared to a net loss of $25.8 million in the same period in 2023. This turnaround is primarily due to increased revenues from product sales and collaborations.
| Net Income Summary | 2024 | 2023 | Change |
|---|---|---|---|
| Net Income (Loss) | $3.1 million | ($25.8 million) | $28.9 million |
Future Financial Outlook
Rigel's future revenue potential is promising, with over $1.4 billion in potential contingent payments from collaboration agreements, contingent upon the success of their product candidates. The company’s operational model suggests a focus on expanding its commercial efforts and maximizing revenues from existing and new collaborations.
Rigel Pharmaceuticals, Inc. (RIGL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Rigel Pharmaceuticals, Inc. (RIGL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Rigel Pharmaceuticals, Inc. (RIGL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Rigel Pharmaceuticals, Inc. (RIGL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.